Maternal and perinatal outcomes among severe preeclampsia mothers treated with levetiracetam versus magnesium sulfate
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Severe preeclampsia is a major contributor to maternal and neonatal morbidity and mortality worldwide. Magnesium sulfate is the gold standard for seizure prophylaxis, but its use is limited by the need for intensive monitoring and potential adverse effects. Levetiracetam has emerged as a potential alternative due to its favourable safety profile. This study aimed to compare the safety and efficacy of levetiracetam and magnesium sulfate in severe preeclampsia. Methods: A prospective observational study was conducted at a tertiary care hospital from June 2024 to December 2025 among 84 pregnant women with severe preeclampsia (>28 weeks gestation). Participants were equally divided into two groups: magnesium sulfate (n=42) and levetiracetam (n=42). Maternal outcomes (eclampsia, ICU admission, complications, hospital stay) and neonatal outcomes (birth weight, APGAR score, NICU admission) were recorded. Statistical analysis was performed using appropriate tests, with p
Fields of Study & Subjects
Pregnancy and preeclampsia studies
Neurological Complications and Syndromes
Neonatal and fetal brain pathology
Publication details
- Journal / source
- International Journal of Clinical Obstetrics and Gynaecology
- Volume
- 10
- Issue
- 2
- Pages
- 580–584
- Publication date
- 1 March 2026
- Language
- EN